Haloperidol Hikma (Haloperidol Decanoate)

Haloperidol Hikma is indicated for the management of several psychiatric disorders where dopamine blockade is beneficial.

• Treatment of schizophrenia, including maintenance therapy.
• Control of acute psychotic episodes.
• Management of manic episodes associated with bipolar disorder.
• Adjunctive therapy for severe agitation when rapid calming is required.
• Use in patients who require a long‑acting injectable antipsychotic to improve adherence.

Side effects of haloperidol decanoate can vary in frequency and severity. Patients should be monitored for both common and serious reactions.

Common

• Extrapyramidal symptoms such as tremor, rigidity, and akathisia.
• Drowsiness or sedation.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal upset.
• Weight gain or changes in appetite.
• Orthostatic hypotension.

Serious

• Neuroleptic malignant syndrome.
• Tardive dyskinesia.
• Severe depression or suicidal thoughts.
• Cardiac arrhythmias, including QT prolongation.
• Hyperprolactinemia with menstrual disturbances.
• Seizures in susceptible individuals.

Before initiating haloperidol Hikma, clinicians should consider several safety factors to minimize risk.

• Assess cardiovascular status, especially for QT interval prolongation.
• Evaluate for a history of movement disorders or extrapyramidal sensitivity.
• Use caution in patients with hepatic or renal impairment.
• Monitor for signs of neuroleptic malignant syndrome during the first weeks of therapy.
• Discuss pregnancy and lactation considerations with women of childbearing potential.
• Regularly review concomitant medications that may affect dopamine pathways.
• Educate patients and caregivers about the importance of adherence and early reporting of side effects.

Haloperidol decanoate can interact with several drug classes, influencing its efficacy and safety profile.

Avoid

• Other dopamine antagonists or antipsychotics, which may increase extrapyramidal risk.
• Medications that significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).
• Strong CYP3A4 inhibitors that can raise haloperidol plasma levels.

Use with caution

• CNS depressants such as benzodiazepines or opioids, which may enhance sedation.
• Anticholinergic agents that can mask early signs of extrapyramidal symptoms.
• CYP3A4 inducers (e.g., carbamazepine) that may reduce therapeutic effect.
• Lithium, due to potential additive neurotoxic effects.
• Alcohol, which can increase sedation and hypotension.